A Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE) - Trial NCT06411249
Access comprehensive clinical trial information for NCT06411249 through Pure Global AI's free database. This Phase 4 trial is sponsored by GlaxoSmithKline and is currently Not yet recruiting. The study focuses on Systemic Lupus Erythematosus. Target enrollment is 350 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
GlaxoSmithKline
Timeline & Enrollment
Phase 4
Jun 04, 2024
May 29, 2029
Primary Outcome
Part A: Percentage of Participants Achieving Lupus Low Disease Activity State (LLDAS) at Week 52
Summary
This is a prospective, open-label, single arm 3-year clinical study to describe the
 short-term and long-term efficacy and safety of belimumab in participants with autoantibody
 positive early SLE with ongoing disease activity despite stable initial SLE therapy.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06411249
Non-Device Trial